EVERCMV: Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A
Study Details
Study Description
Brief Summary
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals. The goal of this study is to demonstrate that an immunosuppressive regimen associating everolimus and reduced dose of cyclosporine A can prevent acute rejection episodes as efficiently as standard regimen but also efficiently reduce the incidence of CMV infection at 6 months post-transplantation.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after kidney transplantation. Therefore most of the patients receive an universal prophylaxis. On the contrary to CMV naïve patients, seropositive recipients (R+) have already mounted a specific immunologic response directed against the virus, which is not completely abrogated by immunosuppressive drugs. Although CMV infection management guidelines offer little guidance on immunosuppressive therapy for preventing CMV infection and disease, recent data plead for reappraising the place of mTOR inhibitors in this situation. The potential anti-CMV action of these molecules could be added to their potential antitumor effect and their equivalent immunosuppressive efficacy in kidney transplant recipients at low immunological risk. By the way, it could represent an alternative of a systematic universal prophylaxis in R+ kidney transplant recipients. However, the proof of this anti-CMV action must be confirmed in vivo in a study, which could have a close monitoring of CMV infection.
We therefore designed a prospective multicentric randomized controlled trial comparing an immunosuppressive regimen based on everolimus and reduced dose of cyclosporine A to a regimen based on mycophenolic acid and standard dose of cyclosporine A, in order to demonstrate the superiority of the first one in the prevention of CMV infection.
Subjects will be randomized to one of the two treatment arms and will be followed for a period of 12 months. Whole blood CMV real time PCR will be performed every week during the first three months, then every two weeks from Month 3 to Month 6, then at Months 8, 10 and 12. Incidence of CMV infection will be compared between the two arms at 6 and 12 months post-transplantation.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Everolimus Everolimus + reduced dose of cyclosporine A |
Drug: Everolimus
Everolimus : 0.75 bid, targeted to 3-8 ng/ml
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
|
| Active Comparator: mycophenolic acid mycophenolic acid + standard dose of cyclosporin A |
Drug: mycophenolic acid
Mycophenolic acid :
1080 mg bid for one month, then 720 mg bid
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
|
Outcome Measures
Primary Outcome Measures
- Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients. [6 months post-transplantation]
The primary objective of this study is to compare the survival without CMV infection and without graft loss in CMV seropositive kidney transplant recipients, within the first 6 months post-transplantation when treated with an immunosuppressive regimen including everolimus (Certican®) and reduced dose (RD) of cyclosporine A (Néoral®) versus an immunosuppressive regimen with mycophenolic acid (Myfortic®) and standard dose (SD) of cyclosporine A (Néoral®).
Secondary Outcome Measures
- Proportion of patients who will develop CMV disease [6 and 12 months post-transplantation]
The proportion of patients who will develop CMV disease during the first 6 and 12 months post-transplantation (CMV disease includes both CMV syndrome and CMV tissue-invasive disease).
- Proportion of patient with graft loss, death and loss of follow-up [12 months post-transplantation]
- Proportion of patient with acute rejection, graft loss, death and loss of follow-u [12 months]
- Level to the first CMV DNAemia [Throughout the study]
- Time to the first CMV disease [Throughout the study]
- Proportion of patients treated for CMV infection in both groups [6 months]
- Half-life of decreasing of DNAemia [after initiation of anti-CMV therapy]
- Occurrence of treatment failure, defined as the absence of viral eradication. [Day 49 (or 8 weeks) after the initiation of anti-CMV therapy]
- Occurrence of CMV mutation (UL97 ou UL54) associated with a resistance to an anti-CMV therapy. [Throughout the study]
- Graft function [6 and 12 months post-transplantation]
Graft function defined as glomerular filtration rate (GFR) estimated by simplified MDRD formula and proteinuria/creatininuria ratio.
- Proportion of patients with biopsy-proven acute rejection (BPAR) [6 and 12 months post-transplantation]
- Degree of interstitial fibrosis/tubular atrophy [12 months on protocol biopsies]
- Graft and patient survival [6 and 12 months post-transplantation]
- Proportion of BK virus viremia [month 1, 3, 6 and 12]
- Proportion of patients with adverse events (AE) and/or serious adverse events (SAE) including opportunistic infections and neoplasias. [12 months]
- Proportion of patients with haematological disorders [12 months]
The proportion of patients with haematological disorders (neutropenia, anaemia, thrombopenia)
- Proportion of patients with diarrhea [12 months]
- Proportion of dyslipidemia [12 months]
- Proportion of patients with occurrence of New Onset Diabetes Mellitus as defined by American Diabetic Association (ADA) criteria. [12 months]
- Proportion of patients who will discontinue the immunosuppressive treatment and the reasons why. [12 months]
- Proportion of patients with delayed graft function [12 months]
- Proportion of lymphocele [12 months]
- Time to the first CMV DNAemia [Throughout the study]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years.
-
End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation.
-
Patient seropositive for CMV (confirmed within two weeks post-transplant) and having received an allograft from a CMV seropositive or seronegative donor.
-
Receiving a kidney transplant from a deceased or living donor with compatible ABO blood type.
-
Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study and two months later the discontinuation of the test drug.
-
Total ischemia time below 36 hours.
-
Capable of understanding the purpose and risks of the study.
-
Fully informed and having given written informed consent (signed Informed Consent has been obtained).
-
Affiliation to the social security regimen
Exclusion Criteria:
-
CMV seronegative patient.
-
Historical or current TGI (French equivalence of calculated PRA) > 85 %
-
Presence of historical or current anti-HLA donor specific antibodies
-
Patient who received anti-CMV therapy within the past 30 days prior to screening.
-
Receiving or having previously received an organ transplant other than a kidney.
-
Receiving a graft from a non-heart-beating donor.
-
Patient known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV; HBs Ag positive) or Hepatitis C (HCV; anti-HCV Ab positive).elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels ≥ 2 times the upper value of the normal range of the investigational site or receiving a graft from a hepatitis C or B positive donor.
-
Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.
-
Known allergy or intolerance to everolimus, valganciclovir, ganciclovir, mycophenolic acid, basiliximab, corticosteroids, or cyclosporine A or any of the product excipients.
-
Severe hyperlipidemia defined by: total cholestérol ≥ 9,1 mmol/L (≥ 350 mg/dL) et/ou triglycérides ≥ 8,5 mmol/l (≥ 750 mg/dL) in spite an adequate medication.
-
Patient has adequate hematological post-transplant defined as:
-
Absolute neutrophil count (ANC) > 1000 cells/μL.
-
Platelet count > 50,000 cells/μL.
-
Hemoglobin > 8.0 g/dL.
-
Requiring initial therapy with induction immunosuppressive antibody preparations, such as anti-thymocyte globulins or rituximab or IVIG.
-
Currently participating in another clinical trial investigating drugs. Observational studies are not considered as an exclusion criteria
-
Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.
-
Unlikely to comply with the visits scheduled in the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Bordeaux | Bordeaux | France | 33000 | |
| 2 | CHU La Cavale Blanche | Brest | France | 29609 | |
| 3 | CHRU Caen - Hôpital de Caen | Caen | France | 14033 | |
| 4 | CHU de Limoges - Hôpital Dupuytren | Limoges | France | ||
| 5 | Hôpital Edouard Herriot | Lyon | France | 69003 | |
| 6 | APHP - Hôpital Necker | Paris | France | 75015 | |
| 7 | APHP - Kremlin Bicetre | Paris | France | 94275 | |
| 8 | CHRU Strasbourg | Strasbourg | France | ||
| 9 | CHU de Toulouse - Hôpital Rangueil | Toulouse | France | 31000 |
Sponsors and Collaborators
- University Hospital, Bordeaux
- Novartis
Investigators
- Principal Investigator: Lionel COUZI, MD, University Hospital, Bordeaux
- Study Chair: Rodolphe THIEBAUT, MD, PhD, University Hospital, Bordeaux
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHUBX2012/29